SCHEDULE 13G/A: Invus Public Equities Reduces Stake in Syros Pharmaceuticals Below 5%
Beneficial Ownership Disclosure
Invus Public Equities, L.P. and its affiliated entities have reported a reduction in their beneficial ownership of Syros Pharmaceuticals, Inc. common stock to 3.8%, falling below the 5% threshold.
Summary
- Invus Public Equities, L.P., along with its related entities including Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Ulys, L.L.C., and Raymond Debbane, filed an Amendment No. 5 to Schedule 13G.
- The filing indicates that as of December 31, 2024, the aggregate beneficial ownership of Syros Pharmaceuticals, Inc. common stock by these reporting persons is 1,063,829 shares.
- This amount represents 3.8% of the class of common stock, calculated based on 26,832,457 shares outstanding as of October 24, 2024, plus the 1,063,829 shares issuable upon exercise of warrants.
- Invus Public Equities directly holds warrants to purchase 1,063,829 shares with an exercise price of $10.34 per share, expiring on September 16, 2027.
- The reporting persons have certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership. While the reduction in stake below 5% could be viewed negatively, the document itself is factual and does not contain qualitative language to assess sentiment beyond the numerical change.
Negatives
- Invus Public Equities, L.P. and its affiliated entities have reduced their beneficial ownership in Syros Pharmaceuticals, Inc. to 3.8% of the common stock, including warrants, indicating they now hold less than 5% of the class. This suggests a reduction in their stake or a significant dilution, which could be interpreted as a decrease in investor conviction.
Future Outlook
The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a routine disclosure of a passive investment stake in a biotechnology company. It does not provide specific industry context beyond the nature of the investment.
Stakeholder Impact
- Shareholders: The reduction in a significant investor's stake below the 5% threshold may be interpreted by other shareholders as a signal of reduced confidence or a strategic divestment, potentially influencing their investment decisions.
Key Dates
| Date | Description |
|---|---|
| 2024-10-24 | Date of 26,832,457 shares outstanding as reported in Syros Pharmaceuticals, Inc.'s Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-02-12 | Date of filing of this Schedule 13G Amendment No. 5. |
| 2027-09-16 | Expiration date of warrants held by Invus Public Equities. |
Keywords
Syros Pharmaceuticals, Invus Public Equities, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Shareholder Stake, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.